[HTML][HTML] Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients
PS Zeiner, M Kinzig, I Divé, GD Maurer… - Journal of Clinical …, 2019 - mdpi.com
(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial
indicated a survival benefit for patients with first recurrence of a glioblastoma when treated …
indicated a survival benefit for patients with first recurrence of a glioblastoma when treated …
Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.
PS Zeiner, M Kinzig, I Divé, GD Maurer… - Journal of Clinical …, 2019 - europepmc.org
Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated
a survival benefit for patients with first recurrence of a glioblastoma when treated with the …
a survival benefit for patients with first recurrence of a glioblastoma when treated with the …
[PDF][PDF] Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
PS Zeiner, M Kinzig, I Divé, GD Maurer… - J. Clin …, 2019 - pdfs.semanticscholar.org
(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial
indicated a survival benefit for patients with first recurrence of a glioblastoma when treated …
indicated a survival benefit for patients with first recurrence of a glioblastoma when treated …
[HTML][HTML] Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
PS Zeiner, M Kinzig, I Divé, GD Maurer… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated
a survival benefit for patients with first recurrence of a glioblastoma when treated with the …
a survival benefit for patients with first recurrence of a glioblastoma when treated with the …
Regorafenib CSF penetration, efficacy, and MRI patterns in recurrent malignant glioma patients
PS Zeiner, M Kinzig, I Divé… - Journal of …, 2019 - publikationen.ub.uni-frankfurt.de
(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial
indicated a survival benefit for patients with first recurrence of a glioblastoma when treated …
indicated a survival benefit for patients with first recurrence of a glioblastoma when treated …
Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.
PS Zeiner, M Kinzig, I Divé, GD Maurer… - Journal of Clinical …, 2019 - search.ebscohost.com
Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial indicated
a survival benefit for patients with first recurrence of a glioblastoma when treated with the …
a survival benefit for patients with first recurrence of a glioblastoma when treated with the …
Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
PS Zeiner, M Kinzig, I Divé… - Journal of clinical …, 2019 - pubmed.ncbi.nlm.nih.gov
(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial
indicated a survival benefit for patients with first recurrence of a glioblastoma when treated …
indicated a survival benefit for patients with first recurrence of a glioblastoma when treated …
[PDF][PDF] Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients
PS Zeiner, M Kinzig, I Divé, GD Maurer… - J. Clin …, 2019 - pdfs.semanticscholar.org
(1) Background: The phase 2 Regorafenib in Relapsed Glioblastoma (REGOMA) trial
indicated a survival benefit for patients with first recurrence of a glioblastoma when treated …
indicated a survival benefit for patients with first recurrence of a glioblastoma when treated …